ANI Pharmaceuticals ANIP Accrued Royalties (Current)
Accrued Royalties (Current) at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's accrued royalties (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's accrued royalties (current)?
- ANI Pharmaceuticals (ANIP) reported accrued royalties (current) of $33.93M in Q1 2026.
- How has ANI Pharmaceuticals's accrued royalties (current) changed year-over-year?
- ANI Pharmaceuticals's accrued royalties (current) increased by 43.1% year-over-year, from $23.71M to $33.93M.
- What is the long-term trend for ANI Pharmaceuticals's accrued royalties (current)?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's accrued royalties (current) has grown at a 49.9% compound annual growth rate (CAGR), from $6.41M to $48.5M.
- What does accrued royalties (current) mean?
- This represents the liability for royalty payments owed to third-party licensors for the use of intellectual property or patented technologies that have been incurred but not yet settled. These obligations are typically due within the next twelve months and are essential for maintaining access to critical product formulations. High balances may indicate significant reliance on licensed technology or delays in payment cycles.